Summary

Eligibility
for people ages 18-80 (full criteria)
Location
at UC Davis
Dates
study started
completion around
Principal Investigator
by Sergey Stavisky, Ph.D. (ucdavis)

Description

Summary

The goal of this study is to improve our understanding of speech production, and to translate this into medical devices called intracortical brain-computer interfaces (iBCIs) that will enable people who have lost the ability to speak fluently to communicate via a computer just by trying to speak.

Official Title

Understanding and Restoring Speech Production Using an Intracortical Brain-computer Interface

Details

The goal is to develop a new way to help people who lose the ability to speak due to neurological conditions including ALS or stroke, using an implanted medical device called a "brain-computer interface". The implanted medical device measures the person's brain activity as they try to talk and outputs their intended speech. By bypassing the injured parts of the nervous system this way, we can observe how individual brain cells are involved in speaking and working together as a network, to produce speech, and we can learn to decipher this activity to output what the person is trying to say.

Keywords

Anarthria, Dysarthria, Tetraplegia, Spinal Cord Injuries, Amyotrophic Lateral Sclerosis, Brain Stem Infarctions, Locked-in Syndrome, Muscular Dystrophies, Motor Neuron Disease, Quadriplegia, BrainGate Neural Interface System

Eligibility

You can join if…

Open to people ages 18-80

  • Between 18 and 80 years of age
  • Clinical diagnosis of spinal cord injury, brainstem stroke, muscular dystrophy, amyotrophic lateral sclerosis or other motor neuron disorders
  • Complete or incomplete tetraplegia (quadriplegia)
  • Must live within a three-hour drive of the Study site and geographically stable for at least 15 months after enrollment.

(There are additional inclusion criteria)

You CAN'T join if...

  • Visual impairment such that extended viewing of a computer monitor would be difficult even with ordinary corrective lenses
  • Chronic oral or intravenous steroids or immunosuppressive therapy
  • Other serious disease or disorder that could seriously affect ability to participate in the study

(There are additional exclusion criteria)

Location

  • University of California, Davis accepting new patients
    Sacramento California 95817 United States

Lead Scientist at University of California Health

  • Sergey Stavisky, Ph.D. (ucdavis)
    Assistant Professor, Med: Neurological Surgery, School of Medicine. Authored (or co-authored) 42 research publications

Details

Status
accepting new patients
Start Date
Completion Date
(estimated)
Sponsor
Leigh R. Hochberg, MD, PhD.
ID
NCT06094205
Study Type
Interventional
Participants
Expecting 2 study participants
Last Updated